These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 17086138)

  • 1. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 4. [Reduced mycobacterial resistance to antituberculous drugs in the experiment and clinic: immediate and long-term results].
    Belianin II; Shmelev EI
    Probl Tuberk Bolezn Legk; 2007; (2):31-8. PubMed ID: 17419333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment duration for patients with drug-resistant tuberculosis, United States.
    Winston CA; Mitruka K
    Emerg Infect Dis; 2012 Jul; 18(7):1201-2. PubMed ID: 22709909
    [No Abstract]   [Full Text] [Related]  

  • 6. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of microchip technology in determination of drug resistance of Mycobacterium tuberculosis].
    Vasil'eva IA; Chernousova LN; Zasedatelev AS; Sobolev AIu; Mikhaĭlovich VM
    Probl Tuberk; 2002; (6):21-4. PubMed ID: 12227044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
    Chakraborty S; Rhee KY
    Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.
    Morales Pérez C; Gomez-Pastrana D; Aragón Fernández C; Pérez Escolano E
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):388-390. PubMed ID: 30635203
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.
    Somoskovi A; Parsons LM; Salfinger M
    Respir Res; 2001; 2(3):164-8. PubMed ID: 11686881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The past, present and future of tuberculosis treatment.
    Bi K; Cao D; Ding C; Lu S; Lu H; Zhang G; Zhang W; Li L; Xu K; Li L; Zhang Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):657-668. PubMed ID: 36915970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in drug resistance of Mycobacteria in the simultaneous use of chemotherapy and intravenous infusions of dissolved ozone].
    Belianin II; Shmelev EI
    Probl Tuberk Bolezn Legk; 2004; (7):32-5. PubMed ID: 15379039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.